These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
504 related articles for article (PubMed ID: 19447923)
1. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Quittner AL; Modi AC; Wainwright C; Otto K; Kirihara J; Montgomery AB Chest; 2009 Jun; 135(6):1610-1618. PubMed ID: 19447923 [TBL] [Abstract][Full Text] [Related]
3. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109 [TBL] [Abstract][Full Text] [Related]
4. Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study. Blasi F; Carnovale V; Cimino G; Lucidi V; Salvatore D; Messore B; Bartezaghi M; Muscianisi E; Porpiglia PA; Respir Med; 2018 May; 138():88-94. PubMed ID: 29724399 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Retsch-Bogart GZ; Quittner AL; Gibson RL; Oermann CM; McCoy KS; Montgomery AB; Cooper PJ Chest; 2009 May; 135(5):1223-1232. PubMed ID: 19420195 [TBL] [Abstract][Full Text] [Related]
6. Changes in the parent cystic fibrosis questionnaire-revised (CFQ-R) with respiratory symptoms in preschool children with cystic fibrosis. Perrem L; Stanojevic S; Shaw M; Davis S; Retsch-Bogart G; Ratjen F J Cyst Fibros; 2020 May; 19(3):492-498. PubMed ID: 32139196 [TBL] [Abstract][Full Text] [Related]
7. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection. Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995 [TBL] [Abstract][Full Text] [Related]
8. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Lang AB; Rüdeberg A; Schöni MH; Que JU; Fürer E; Schaad UB Pediatr Infect Dis J; 2004 Jun; 23(6):504-10. PubMed ID: 15194830 [TBL] [Abstract][Full Text] [Related]
9. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Oermann CM; Retsch-Bogart GZ; Quittner AL; Gibson RL; McCoy KS; Montgomery AB; Cooper PJ Pediatr Pulmonol; 2010 Nov; 45(11):1121-34. PubMed ID: 20672296 [TBL] [Abstract][Full Text] [Related]
10. Longitudinal trends in health-related quality of life in adults with cystic fibrosis. Dill EJ; Dawson R; Sellers DE; Robinson WM; Sawicki GS Chest; 2013 Sep; 144(3):981-989. PubMed ID: 23670667 [TBL] [Abstract][Full Text] [Related]
11. Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis. Palser S; Smith S; Nash EF; Agarwal A; Smyth AR Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012300. PubMed ID: 31845758 [TBL] [Abstract][Full Text] [Related]
16. Longitudinal assessment of exercise capacity and quality of life outcome measures in cystic fibrosis: A year-long prospective pilot study. Bhatia R; Kaye M; Roberti-Miller A J Eval Clin Pract; 2020 Feb; 26(1):236-241. PubMed ID: 30761692 [TBL] [Abstract][Full Text] [Related]
17. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Kosorok MR; Zeng L; West SE; Rock MJ; Splaingard ML; Laxova A; Green CG; Collins J; Farrell PM Pediatr Pulmonol; 2001 Oct; 32(4):277-87. PubMed ID: 11568988 [TBL] [Abstract][Full Text] [Related]
18. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. Stuart Elborn J; Geller DE; Conrad D; Aaron SD; Smyth AR; Fischer R; Kerem E; Bell SC; Loutit JS; Dudley MN; Morgan EE; VanDevanter DR; Flume PA J Cyst Fibros; 2015 Jul; 14(4):507-14. PubMed ID: 25592656 [TBL] [Abstract][Full Text] [Related]
19. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. Konstan MW; Flume PA; Kappler M; Chiron R; Higgins M; Brockhaus F; Zhang J; Angyalosi G; He E; Geller DE J Cyst Fibros; 2011 Jan; 10(1):54-61. PubMed ID: 21075062 [TBL] [Abstract][Full Text] [Related]
20. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study. Sommerwerck U; Virella-Lowell I; Angyalosi G; Viegas A; Cao W; Debonnett L Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]